Immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) cause morbidity and necessitate cessation of treatment. Comparing irAE treatments, we find that anti-tumor immunity is preserved in mice after extracorporeal photopheresis (ECP) but reduced with glucocorticosteroids, TNFα blockade, and α4β7-integrin inhibition. Local adiponectin production elicits a tissue-specific effect by reducing pro-inflammatory T cell frequencies in the colon while sparing tumor-specific T cell development. A prospective phase-1b/2 trial (EudraCT-No.2021-002073-26) with 14 patients reveals low ECP-related toxicity. Overall response rate for all irAEs is 92% (95% confidence interval [CI]: 63.97%-99.81%); colitis-specific complete remission rate is 100% (95% CI: 63.06%-100%). Glucocorticosteroid dosages could be reduced for all patients after ECP therapy. The ECP-adiponectin axis reduces intestinal tissue-resident memory T cell activation and CD4IFN-γ T cells in patients with ICI-induced colitis without evidence of loss of anti-tumor immunity. In conclusion, we identify adiponectin as an immunomodulatory molecule that controls ICI-induced irAEs without blocking anti-tumor immunity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccell.2025.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of exosomes in regulating ferroptosis of tumor cells.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
October 2024
Medical Research Experimental Center, Shaanxi University of Chinese Medicine, Xianyang Shaanxi 712046, China.
Exosomes are nanoscale extracellular vesicles widely present in various body fluids. They carry a variety of substances, including proteins, lipids, and nucleic acids, and play significant roles in the body by participating in immune regulation, intercellular signal transduction, and the transport of proteins and nucleic acids. Exosomes can regulate tumor development and drug resistance by modulating ferroptosis.
View Article and Find Full Text PDFImmo-bile-izing CD8 T cell anti-tumor immunity.
Immunity
March 2025
Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, NSW 2145, Australia; Blacktown Mt Druitt Hospital, Sydney, NSW 2148, Australia. Electronic address:
Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8 T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.
View Article and Find Full Text PDFA Self-Priming Pyroptosis-Inducing Agent for Activating Anticancer Immunity.
Adv Healthc Mater
March 2025
Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Pyroptosis, a form of programmed cell death mediated by the gasdermin family, has emerged as a promising strategy for inducing anti-tumor immunity. However, efficiently inducing pyroptosis in tumor cells remains a significant challenge due to the limited activation of key mediators like caspases in tumor tissues. Herein, a self-priming pyroptosis-inducing agent (MnNZ@OMV) is developed by integrating outer membrane vesicles (OMVs) with manganese dioxide nanozymes (MnNZ) to trigger pyroptosis in tumor cells.
View Article and Find Full Text PDFExpression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming.
Front Immunol
March 2025
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Oncolytic viruses (OVs) selectively replicate within tumors, directly killing cancer cells and promoting a systemic immune response by releasing tumor antigens. These features make OVs a promising approach in tumor immunotherapy, offering targeted treatment with fewer side effects. Despite these advantages, OVs are primarily administered via intratumoral injection, limiting their effectiveness for advanced, systemic cancers.
View Article and Find Full Text PDFCo-expression of B7-H3 and LAG3 represents cytotoxicity of CD4 T cells in humans.
Front Immunol
March 2025
Department of Immunology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Recent studies have highlighted the potential contribution of CD4 T cells with cytotoxic activity (CD4 CTLs) to anti-tumor immunity. However, their precise roles remain elusive, partly due to the absence of specific markers defining CD4 CTLs with target-killing potential in humans. We previously demonstrated that Epstein-Barr virus (EBV)-driven immortalized B cell lines efficiently induce human CD4 CTLs with cytotoxic functions comparable to cytotoxic CD8 T cells (CD8 CTLs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!